title: Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system.
abstract: ProAngiotensin-12 (PA12) is the most recent peptide to be identified as a functional component of the renin-angiotensin system (RAS). PA12 is reported to constrict rat coronary arteries and the aorta, dependent upon angiotensin II-converting enzyme 1 (ACE1) and chymase. The current study employed myography to determine the direct vascular effects of PA12 on a range of isolated rat arteries extending from the core to periphery. PA12 significantly constricted the descending thoracic aorta, right and left common carotid arteries, abdominal aorta and superior mesenteric artery, with little effect on the femoral and renal arteries. AngII was found to produce similar responses to PA12 when administered at the same dose. A potency gradient in response to PA12 was clearly apparent, with vessels in closest proximity to the heart responding with the greatest constriction; while constrictive potency was lost further form the heart. Inhibition of ACE1 and chymase both significantly attenuated PA12-induced vasoconstriction, with chymostatin displaying lesser potency. We postulate ACE1 primarily regulates RAS activity within the circulation, while chymase may have an important role in local, tissue-based RAS activity.
authors.affiliation: Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2042, Australia. hamishprosser@gmail.com
authors.forename: H C
authors.initials: HC
authors.lastname: Prosser
authors.forename: A M
authors.initials: AM
authors.lastname: Richards
authors.forename: M E
authors.initials: ME
authors.lastname: Forster
authors.forename: C J
authors.initials: CJ
authors.lastname: Pemberton
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000808:Angiotensinogen / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001158:Arteries / Q000187:drug effects*; D002216:Captopril / Q000494:pharmacology; D053818:Chymases / Q000037:antagonists & inhibitors / Q000502:physiology; D004355:Drug Stability; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D066298:In Vitro Techniques; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D009928:Organ Specificity; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D007703:Peptidyl-Dipeptidase A / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology; D013997:Time Factors; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D009842:Oligopeptides; D010446:Peptide Fragments; D015842:Serine Proteinase Inhibitors; D014662:Vasoconstrictor Agents; C515557:proangiotensin-12, rat; D000808:Angiotensinogen; D000804:Angiotensin II; C002101:chymostatin; D002216:Captopril; D007703:Peptidyl-Dipeptidase A; D053818:Chymases